Surrozen (Surrozen) Cash-to-Debt : 10.67 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Surrozen Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Surrozen's cash to debt ratio for the quarter that ended in Dec. 2023 was 10.67.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Surrozen could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Surrozen's Cash-to-Debt or its related term are showing as below:

SRZN' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.13 Med: 11.87 Max: 13.54
Current: 10.67

During the past 4 years, Surrozen's highest Cash to Debt Ratio was 13.54. The lowest was 5.13. And the median was 11.87.

SRZN's Cash-to-Debt is ranked better than
56.43% of 1540 companies
in the Biotechnology industry
Industry Median: 6.52 vs SRZN: 10.67

Surrozen Cash-to-Debt Historical Data

The historical data trend for Surrozen's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Surrozen Cash-to-Debt Chart

Surrozen Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

5.13

13.07

13.54

10.67

Surrozen Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial									13.54	12.16	11.79	10.97	10.67

Competitive Comparison of Surrozen's Cash-to-Debt

For the Biotechnology subindustry, Surrozen's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Surrozen's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Surrozen's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Surrozen's Cash-to-Debt falls into.

Surrozen Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Surrozen's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	36.043	/	(2.497	+	0.882)
	=	10.67

Surrozen's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	36.043	/	(2.497	+	0.882)
	=	10.67

Surrozen (NAS:SRZN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Surrozen Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Surrozen's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Surrozen (Surrozen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surrozen Inc (NAS:SRZN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

171 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.surrozen.com

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), and SZN-043 (E3/ASGR1, SWEETS).

Executives

Yang Li	officer: Exec. Vice President, Research	C/O SURROZEN, INC., 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Anna Berkenblit	director	830 WINTER STREET, WALTHAM MA 02451
Eric Bjerkholt	director	132 PURDURE AVENUE, KENGSINGTON CA 94708
Blutt Mitchell J Md	director, 10 percent owner	1370 AVENUE OF THE AMERICA, SUITE 3301, NEW YORK NY 10019
Christopher Y Chai	director	2400 BAYSHORE PARKWAY, SUITE 200, MOUNTAIN VIEW CA 94043
Mary Haak-frendscho	director	171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Wen-chen Yeh	officer: Chief Scientific Officer	171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
House Joshua Cory	other: Former VP Business Development	C/O CONSONANCE-HWF ACQUISITION CORP, 1 PALMER SQUARE, SUITE 305, PRINCETON NJ 08540
Geertrui Vanhove	officer: Chief Medical Officer	1333 S. SPECTRUM BLVD #100, CHANDLER AZ 85286
Charles O Williams	officer: Chief Financial Officer	C/O HERITAGE FINANCIAL GROUP, 721 NORTH WESTOVER BOULEVARD, ALBANY GA 31707
Mace Rothenberg	director	171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Donald J Santel	other: Former Director	4362 24TH STREET, SAN FRANCISCO CA 94114
David J Woodhouse	director	630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Column Group Iii Gp, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158